Editas Medicine

Editas Medicine is a clinical-stage genome editing company headquartered in Cambridge, Massachusetts, developing durable, precision CRISPR-based gene editing medicines for people with serious diseases. The company works across in vivo and ex vivo approaches and holds foundational CRISPR/Cas9 and Cas12a intellectual property, advancing a pipeline that has included programs in sickle cell disease, beta-thalassemia and inherited retinal disorders. Editas Medicine trades on Nasdaq under the ticker EDIT and was surfaced in the API Evangelist network as a portfolio company of GV (Google Ventures). As a life-sciences research and therapeutics organization it publishes a corporate and investor-relations web presence rather than a public developer API, so this profile captures its identity, web properties, and probed domain-security posture.

Editas Medicine is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Gene Editing, and CRISPR.

Editas Medicine’s developer surface includes engineering blog, support, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyLife SciencesBiotechnologyGene EditingCRISPRGenomicsTherapeuticsPharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.0/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/editas-medicine: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: editas-medicine
name: Editas Medicine
description: Editas Medicine is a clinical-stage genome editing company headquartered in Cambridge, Massachusetts, developing
  durable, precision CRISPR-based gene editing medicines for people with serious diseases. The company works across in vivo
  and ex vivo approaches and holds foundational CRISPR/Cas9 and Cas12a intellectual property, advancing a pipeline that has
  included programs in sickle cell disease, beta-thalassemia and inherited retinal disorders. Editas Medicine trades on Nasdaq
  under the ticker EDIT and was surfaced in the API Evangelist network as a portfolio company of GV (Google Ventures). As
  a life-sciences research and therapeutics organization it publishes a corporate and investor-relations web presence rather
  than a public developer API, so this profile captures its identity, web properties, and probed domain-security posture.
url: https://raw.githubusercontent.com/api-evangelist/editas-medicine/refs/heads/main/apis.yml
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.editasmedicine.com/wp-content/themes/sage/dist/images/logo-editas-gray_f449d648.svg
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Gene Editing
- CRISPR
- Genomics
- Therapeutics
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.editasmedicine.com
- type: Blog
  url: https://ir.editasmedicine.com/news-releases
- type: Support
  url: https://www.editasmedicine.com/contact/
- type: PrivacyPolicy
  url: https://www.editasmedicine.com/privacy-policy/
- type: TermsOfService
  url: https://www.editasmedicine.com/terms-of-use/
- type: DomainSecurity
  url: security/editas-medicine-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence